FindTrial
Sign In

Ilaris

BIOLOGICAL2 trials

Sponsors

Universitaire Ziekenhuizen KU Leuven, Novartis Pharmaceuticals

Conditions

Colchicine Resistance Familial Mediterranean Fever (crFMF)Cryopyrin-associated Periodic Syndromes (CAPS)Hereditary Periodic Fever SyndromesHyper-IgD Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD)Schnitzler SyndromeSystemic Juvenile Idiopathic Arthritis (sJIA)TNF Receptor Associated Periodic Syndrome (TRAPS)

Phase 2

Ilaris (Canakinumab) in the Schnitzler Syndrome
CompletedNCT01245127
Universitaire Ziekenhuizen KU LeuvenSchnitzler Syndrome
Start: 2011-05-31End: 2012-05-31Updated: 2019-07-05

Unknown Phase

Ilaris NIS in Korea
RecruitingNCT06838143
Novartis PharmaceuticalsColchicine Resistance Familial Mediterranean Fever (crFMF), Cryopyrin-associated Periodic Syndromes (CAPS), Hereditary Periodic Fever Syndromes +3
Start: 2025-03-29End: 2028-09-30Target: 25Updated: 2026-05-19

Related Papers

Canakinumab in Schnitzler syndrome.
2012-08-1525 citations